Approvals for Shire’s attention deficit / hyperactivity disorder (ADHD) treatment Elvanse® is imminent in eight European states. Elvanse is specifically indicated as part of a comprehensive treatment ...
Shire is celebrating the news that approvals in eight European states are imminent for its attention deficit/hyperactivity disorder blockbuster Vyvanse, which will be marketed as Elvanse. Shire is ...
UK patients with attention deficit hyperactivity disorder (ADHD) will soon get access to a new treatment option for their condition following the approval of Shire's Elvanse in the country. UK ...
Nyon, Switzerland – February 19, 2014 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the acceptance for review of an application for an adult indication, for their once-daily Attention ...
Shire launches Elvanse Adult ®Description: BT_1000x858px (lisdexamfetamine dimesylate), the first licensed stimulant treatment for adults with ADHD in the UK Basingstoke, UK – 26 August 2015 – Shire ...
The inactive prodrug is absorbed from the gut into the bloodstream where it is gradually converted to the active part of the medicine, d-amfetamine (d-AMF).[12] The active part of Elvanse is thought ...
Hosted on MSN
City analyst, 28, died days after ADHD medication was increased as coroner calls for drug review
A coroner has urged a review following the death of a young City finance worker of heart issues just days after his ADHD medication dosage was increased. Coroner Sarah Bourke has called on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results